Safety and Immunogenicity of Innocell Autologous Cellular Immunotherapy in Recurrent Epithelial Ovarian Cancer - Trial NCT06366490
Access comprehensive clinical trial information for NCT06366490 through Pure Global AI's free database. This Phase 1 trial is sponsored by PhotonPharma, Inc. and is currently Not yet recruiting. The study focuses on Ovarian Cancer. Target enrollment is 8 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
PhotonPharma, Inc.
Timeline & Enrollment
Phase 1
Jun 01, 2024
Mar 01, 2025
Primary Outcome
Saferty and Immunogenicity of Innocell in Ovarian Cancer Patients,Safety of Innocell in Ovarian Cancer Patients,Immunogenicity of Innocell in Ovarian Cancer Patients,Immunogemicity in Ovarian Cancer Patients,Immunogenicity of Innocell Vaccine in Ovarian Cancer Patients
Summary
Safety and Immunogenicity of InnocellTM Autologous Cellular Immunotherapy Administered in
 Patients with Recurrent Epithelial Ovarian Cancer
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06366490
Non-Device Trial